To assess whether TH1902 could serve a SORT1 receptor-mediated chemotherapeutic approach in an immunocompetent syngeneic model, we first assessed SORT1 expression in murine B16-F10 melanoma cells along with other cell lines. This evidence concerns the gene SORT1 and melanoma.